CN102871955A - Ointment medicament composition containing mupirocin - Google Patents
Ointment medicament composition containing mupirocin Download PDFInfo
- Publication number
- CN102871955A CN102871955A CN2012104205995A CN201210420599A CN102871955A CN 102871955 A CN102871955 A CN 102871955A CN 2012104205995 A CN2012104205995 A CN 2012104205995A CN 201210420599 A CN201210420599 A CN 201210420599A CN 102871955 A CN102871955 A CN 102871955A
- Authority
- CN
- China
- Prior art keywords
- mupirocin
- polyethylene glycol
- molecular weight
- pharmacy
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an ointment medicament composition containing mupirocin, and particularly relates to an ointment medicament composition. The ointment medicament composition comprises mupirocin or pharmaceutically acceptable salt thereof, polyethylene glycol and inorganic acid, wherein mupirocin or pharmaceutically acceptable salt thereof are shown in the specification. The polyethylene glycol described by the invention comprises polyethylene glycol the molecular weight of which is 200-600 and polyethylene glycol the molecular weight of which is 2000-6000. The ointment medicament composition disclosed by the invention has good pharmaceutical characteristics.
Description
Technical field
The present invention relates to the new ointment medicament compositions that comprises mupirocin, and the preparation method of said composition.
Background technology
Mupirocin (Mupirocin) has another name called Mupirocin, (Pseudomonas fluorescens) isolates by pseudomonas fluorescens, be a kind of more satisfactory skin surface antibiotic preparation, (Bactroban) introduced to the market as trade name take " Mupirocin Ointment " by GlaxoSmithKline PLC in 1985.U.S. FDA was ratified this medicine and is used in U.S.'s listing in 1987, China was approval Sino-U.S.'s SmithKline pharmaceutical manufacturing in 1993 and sell this medicine.Mupirocin is mainly used in the bacterial skin infections disease of preventing and treating gram-positive cocci to cause, primary cutaneous such as impetigo, furuncle and phyma, folliculitis infects, and reaches the Secondary cases skin infection diseases such as eczema concurrent infection, ulcer concurrent infection, wound concurrent infection.The dominant mechanism of mupirocin antibacterial action is the protein synthesis in the anti-bacteria body.Particularly, mupirocin acts on the binding site of the interior isoleucine of bacterial body-tRNA synzyme and isoleucine, thereby synthesizing of hindered aminoacid also consumed intracellular tRNA, and the building-up process of the synthetic and protein of RNA is ended.
The chemistry of mupirocin is called 9-[[(2E)-4-[(2S, 3R, 4R, 5S)-5-[(2S, 3S; 4S, 5S)-2,3-epoxy-5-hydroxy-4-methyl hexyl]-3,4-dihydroxy-3; 4,5,6-tetrahydrochysene-2H-pyrans-2-yl]-3-methyl but-2-ene acyl group] the oxygen base] n-nonanoic acid, molecular formula is C
26H
44O
9, molecular weight is 500.6, chemical structural formula is:
At present, in the clinical practice, the main preparation of mupirocin has two kinds of mupirocin calcium cream (take mupirocin calcium as active component) and mupirocin ointments (take mupirocin as active component).The mupirocin ointment of existing Sino-America Tianjin Shike Pharmaceutical Co., Ltd. production and selling, its active component are mupirocin, and ointment base is PEG400 (mean molecule quantity is 400, and is lower same) and PEG3350.
However, the product preparation of clinical use particularly of the new method preparation of mupirocin is still expected to have in this area, and this new preparation expectation has the good pharmacy characteristics of at least one aspect.
Summary of the invention
The object of the present invention is to provide a kind of method of new preparation mupirocin, being mixed with the particularly preparation of clinical use of product, and give the good pharmacy characteristics that this new preparation has at least one aspect.The inventor is surprised to find the effect that the mupirocin ointment medicament compositions with prescription of the present invention has obtained desirable, the present invention is based on this and is accomplished.
Aspect first, provide a kind of ointment medicament compositions of the present invention, wherein comprised: mupirocin shown in the following formula or the acceptable salt of its pharmacy, Polyethylene Glycol and mineral acid,
According to the ointment medicament compositions of first aspect present invention, it comprises mupirocin or the acceptable salt of its pharmacy, molecular weight is that 200 ~ 600 Polyethylene Glycol, molecular weight are 2000 ~ 6000 Polyethylene Glycol and mineral acid.
According to the ointment medicament compositions of first aspect present invention, the acceptable salt of the pharmacy of wherein said mupirocin is calcium salt or its solvate of mupirocin.
According to the ointment medicament compositions of first aspect present invention, the acceptable salt of the pharmacy of wherein said mupirocin is calcium salt or its hydrate of mupirocin.
According to the ointment medicament compositions of first aspect present invention, the acceptable salt of the pharmacy of wherein said mupirocin is the dihydrate of the mupirocin calcium salt shown in the following formula:
According to the ointment medicament compositions of first aspect present invention, wherein said molecular weight is that 200 ~ 600 Polyethylene Glycol is that molecular weight is the Polyethylene Glycol of 200-400.For example described molecular weight is that 200 ~ 600 Polyethylene Glycol is that molecular weight is 200,300,400 Polyethylene Glycol or its combination.
According to the ointment medicament compositions of first aspect present invention, wherein said molecular weight is that 200 ~ 600 Polyethylene Glycol is that molecular weight is 400 Polyethylene Glycol.
According to the ointment medicament compositions of first aspect present invention, wherein said molecular weight is that 2000 ~ 6000 Polyethylene Glycol is that molecular weight is the Polyethylene Glycol of 2000-4000.For example described molecular weight is that 2000 ~ 4000 Polyethylene Glycol is that molecular weight is 2000,3000,3350,4000 Polyethylene Glycol or its combination.
According to the ointment medicament compositions of first aspect present invention, wherein said molecular weight is that 2000 ~ 6000 Polyethylene Glycol is that molecular weight is 3350 Polyethylene Glycol.
According to the ointment medicament compositions of first aspect present invention, wherein said mineral acid is boric acid.
According to the ointment medicament compositions of first aspect present invention, wherein also comprise the acceptable adjuvant of optional pharmacy.It is the adjuvant that is different from above-mentioned Polyethylene Glycol and boric acid.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin or the acceptable salt of its pharmacy: 0.5 ~ 5g,
Molecular weight is 2000 ~ 6000 Polyethylene Glycol: 10 ~ 30g,
Mineral acid: 0.01 ~ 2g,
The optional acceptable adjuvant of pharmacy: 0 ~ 5g, and
Molecular weight is 200 ~ 600 Polyethylene Glycol: an amount of, add to 100g.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin or the acceptable salt of its pharmacy: 1 ~ 3g,
Molecular weight is 2000 ~ 6000 Polyethylene Glycol: 15 ~ 25g,
Mineral acid: 0.1 ~ 1g,
The optional acceptable adjuvant of pharmacy: 0 ~ 2g, and
Molecular weight is 200 ~ 600 Polyethylene Glycol: an amount of, add to 100g.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin or the acceptable salt of its pharmacy: 1 ~ 3g,
Molecular weight is 2000 ~ 4000 Polyethylene Glycol: 15 ~ 25g,
Mineral acid: 0.1 ~ 1g,
The optional acceptable adjuvant of pharmacy: 0 ~ 2g, and
Molecular weight is 200 ~ 400 Polyethylene Glycol: an amount of, add to 100g.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 1.5g
PEG4000： 18g
Boric acid: 0.25g
PEG400: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 2g
PEG3350： 19g
Boric acid: 0.5g
PEG400: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 2.5g
PEG3350： 20g
Boric acid: 0.75g
PEG300: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 3g
PEG3000： 15g
Boric acid: 1g
PEG600: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 2g
PEG6000： 15g
Boric acid: 0.5g
PEG200: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 2g
PEG4000： 15g
Boric acid: 0.6g
Borneolum Syntheticum: 0.5g
PEG300: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin calcium: 3g
PEG2000： 25g
Boric acid: 0.6g
PEG400: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, comprise in its per 100 grams:
Mupirocin: 2.5g
PEG4000： 15g
Boric acid: 0.2g
Herba Menthae: 0.2g
PEG200: an amount of, add to 100 grams.
According to the ointment medicament compositions of first aspect present invention, the wherein said optional acceptable adjuvant of pharmacy is such as but not limited to warming regulator (such as Borneolum Syntheticum, Mentholum, Oleum menthae), antiseptic (such as benzyl alcohol), thickening agent (such as carbomer, molecular weight greater than 6000 Polyethylene Glycol) etc.
Second aspect present invention provides the method for preparing the described ointment medicament compositions of first aspect present invention, and it may further comprise the steps:
(1) making mineral acid and the optional acceptable adjuvant of pharmacy be dissolved in an amount of molecular weight is in 200 ~ 600 the Polyethylene Glycol, to obtain mixture;
(2) in the mixture of step (1), add mupirocin or the acceptable salt of its pharmacy, stirring and dissolving;
(3) be that 2000 ~ 6000 Polyethylene Glycol is heated to melting with molecular weight, then it under agitation joined in step (2) the gained material, stir;
(4) add molecular weight be 200 ~ 600 Polyethylene Glycol to full dose, mix homogeneously, and get final product.
According to the method for second aspect present invention, wherein in the step (1) molecular weight be the addition of 200 ~ 600 Polyethylene Glycol can be this component roughly consumption 50 ~ 95%.Respective components fully dissolve or the prerequisite of mixing under, in step (1), suitably add less molecular weight and be 200 ~ 600 aqueous Polyethylene Glycol and help step (1) easier evenly to step (3) dosing, and can in less liquid dispensing container, operate before the mixed technique at the end of execution in step (4).Because mineral acid of the present invention, mupirocin or the acceptable salt of its pharmacy and the optional dissolubility of the acceptable adjuvant of pharmacy in aqueous Polyethylene Glycol are better, therefore it is favourable using the aqueous Polyethylene Glycol of " in right amount " in advance in the step (1), and this " in right amount " is that those skilled in the art are according to easily control or the adjustment of existing knowledge and experience.In addition, for example hereinafter among the embodiment during consumption of the aqueous Polyethylene Glycol of statement, the amount that " an amount of, as to add to 100 grams " expression adds can not done accurately to determine, as long as the end product total amount reaches 100 grams of respective specified.
Method according to second aspect present invention, wherein in the step (3), after the solid polyethylene glycol melting, when joining in step (2) the gained material, if necessary, step (2) gained material can be warming to 40 ~ 50 ° of C in advance, so that the mixing of materials of solid polyethylene glycol and front is even.
Arbitrary embodiment of applicable equally other the arbitrary embodiment of arbitrary technical characterictic that arbitrary embodiment of either side of the present invention or this either side has or other either side, as long as they can be not conflicting, certainly at where applicable each other, necessary words can be done suitably to modify to individual features.The below is further described with characteristics to various aspects of the present invention.
All documents that the present invention quotes from, their full content is incorporated this paper by reference into, and if the expressed implication of these documents and the present invention when inconsistent, be as the criterion with statement of the present invention.In addition, various terms and phrase that the present invention uses have the general sense of well known to a person skilled in the art, nonetheless, the present invention still wishes at this these terms and phrase to be described in more detail and to explain, the term of mentioning and phrase are as the criterion with the implication that the present invention was explained if any inconsistent with known implication.
In the present invention, active component mupirocin or the acceptable salt of its pharmacy are well known to a person skilled in the art, and can obtain or obtain according to existing literature method from the market purchase.Some technical information of mupirocin or the acceptable salt of its pharmacy have been recorded such as European Pharmacopoeia, Japanese Pharmacopoeia etc.
In the present invention, use two PEGlike coatings, a class is that aqueous low-molecular-weight Polyethylene Glycol, particularly molecular weight is 200 ~ 600 Polyethylene Glycol; Another kind of is that the Polyethylene Glycol of the high molecular of solid, particularly molecular weight are 2000 ~ 6000 Polyethylene Glycol.Two PEGlike coatings are used in combination can be for ointment compositions of the present invention provides good physical property, coating performance for example, and because they are water-soluble high-molecular material and easily eccysis, than the ointment in oleaginous base better patient's compliance is arranged.
In the present invention, when mentioning the molecular weight of Polyethylene Glycol, it has the implication of well known to a person skilled in the art, and usually described molecular weight is the mean molecule quantity of Polyethylene Glycol, for example uses molecular weight and is 400 Polyethylene Glycol and refer to that mean molecule quantity is 400 Polyethylene Glycol.
In the present invention, Polyethylene Glycol can represent with PEG, and for example molecular weight is that 400 Polyethylene Glycol can be expressed as PEG400.
In the present composition, when mentioning the amount of mupirocin or the acceptable salt of its pharmacy, all in the mupirocin free acid.For example when directly adding in the compositions with mupirocin, directly in the amount of mupirocin; And when adding fashionable with the acceptable salt of the pharmacy of mupirocin, its addition is converted to the amount meter that is equivalent to mupirocin, in the time of for example will preparing 100 grams, 2% mupirocin calcium ointment, as feeding intake with following formula calcium salt dihydrate, then theoretical inventory should be 2.15 grams, and this 2.15 gram is equivalent to 2 gram mupirocin free acids:
In the present invention, when mentioning mupirocin calcium, such as not in addition explanation, refer to have the dihydrate of the calcium salt of mupirocin shown in the following formula.
Mupirocin ointment provided by the invention is applicable to the treatment of the primary infections such as skin infection that gram-positive cocci causes such as pyoderma, folliculitis, furuncle and phyma; Can play effect antibiotic and that prevent protopathy to increase the weight of to eczema, dermatitis, erosion, ulcer secondary infection, be conducive to the protopathy treatment; Suppurate very effective to reducing the skin surgery post-operative wound.Suitable is that ointment of the present invention adopts the local application mode, can be by cooled product being seated in the foldable metal or plastic tube.
In addition, ointment of the present invention can also contain for example antiseptic and help the solvent of drug osmotic and the emollient in the ointment of suitable conventional additives.
Can also contain other conventional carriers in the described ointment.
If necessary, in any suitable step of described method, can raw material components is levigate.
If necessary, in described method, also can comprise suitable sterilization steps.
The present invention is not bound by any theory, and unexpectedly finds to have the made ointment pharmaceutical composition of mineral acid that the present invention's prescription particularly has specific ratios of the present invention and has such as but not limited to aspects such as stability and have good pharmaceutical property.
The specific embodiment
Further specify the present invention below by specific embodiment/experimental example, still, should be understood to, these embodiment and experimental example are only used for the more detailed usefulness that specifically describes, and should not be construed as for limiting in any form the present invention.
The present invention carries out generality and/or concrete description to the material and the test method that use in the test.Although for realizing that the employed many materials of the object of the invention and operational approach are well known in the art, the present invention still does to describe in detail as far as possible at this.It will be apparent to those skilled in the art that hereinafter, if do not specify that material therefor of the present invention and operational approach are well known in the art.
I, Preparation Example part
Embodiment 1: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: carry out according to following general step.
(1) make boric acid (in back embodiment or the reference examples if present, add simultaneously the acceptable adjuvant of other pharmacy this moment) be dissolved in an amount of (being about prescription estimate consumption 70%) low-molecular-weight aqueous Polyethylene Glycol in, obtain mixture;
(2) in the mixture of step (1), add active component, stirring and dissolving;
(3) solid polyethylene glycol with high molecular is heated to melting, then it is under agitation joined in step (2) the gained material (about 40 ° of C), stirs;
(4) add low-molecular-weight aqueous Polyethylene Glycol to full dose, mix homogeneously lets cool to room temperature, namely gets ointment medicament compositions of the present invention.
Above-mentioned composition can be divided to install to the ointment packets dress with in the aluminum pipe, every pipe 2g, 5g, 10g or 20g are ointment.
Embodiment 2: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.The aqueous Polyethylene Glycol addition of low-molecular-weight is 50% of prescription expectation consumption in the step (1).
Embodiment 3: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.The aqueous Polyethylene Glycol addition of low-molecular-weight is 95% of prescription expectation consumption in the step (1).
Embodiment 4: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.
Embodiment 5: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.Use PEG200 and PEG400 combination as low-molecular-weight PEG, wherein the PEG400 of recipe quantity adds in step (1).Solid polyethylene glycol with high molecular in the step (3) is heated to melting, then it is under agitation joined in step (2) the gained material under the room temperature state.
Embodiment 6: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.Solid polyethylene glycol with high molecular in the step (3) is heated to melting, then it is under agitation joined in step (2) the gained material (50 ° of C).
Embodiment 7: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.
Embodiment 8: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.Use PEG3350 and PEG4000 as high molecular weight PEGs.PEG20000 joins in the prescription with PEG3350 and PEG4000 melting.
Embodiment 9: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.
Embodiment 10: preparation comprises the ointment compositions (with the preparation of 100 gram amounts) of mupirocin
Prescription:
Method for making: the method for reference example 1 is carried out.
II, reference examples part
Reference examples 1: the ointment compositions of preparation mupirocin
Prescription:
Preparation method: citric acid is dissolved in the PEG400, adds again Macrogol 4000, in 60 ℃ water-bath, be heated to melting, add again mupirocin, make the mupirocin dissolving 60 ℃ stirred in water bath, evenly mix, be cooled to room temperature, namely get mupirocin ointment.
Reference examples 2: the ointment compositions of preparation mupirocin
Prescription:
Preparation method: tartaric acid is dissolved in the PEG400, adds again Macrogol 4000, in 55 ℃ water-bath, be heated to melting, add again mupirocin, make the mupirocin dissolving 55 ℃ stirred in water bath, evenly mix, be cooled to room temperature, namely get mupirocin ointment.
Reference examples 3: the ointment compositions of preparation mupirocin
Prescription:
Preparation method: lactic acid dissolution in PEG400, is added Macrogol 4000 again, in 60 ℃ water-bath, be heated to melting, add again mupirocin, make the mupirocin dissolving 60 ℃ stirred in water bath, evenly mix, be cooled to room temperature, namely get mupirocin ointment.
Reference examples 4: the ointment compositions of preparation mupirocin
Except not adding in prescription the boric acid, other composition is identical with embodiment 2 with method for making.
Reference examples 5: the ointment compositions of preparation mupirocin
Except not adding in prescription the boric acid, other composition is identical with embodiment 9 with method for making.
Reference examples 6: the ointment compositions of preparation mupirocin
Boric acid in will filling a prescription is used instead the citric acid, and other composition is identical with embodiment 1 with method for making.
Reference examples 7: the ointment compositions of preparation mupirocin
Boric acid in will filling a prescription is used instead the citric acid, and other composition is identical with embodiment 2 with method for making.
Reference examples 8: the ointment compositions of preparation mupirocin
Boric acid in will filling a prescription is used instead the citric acid, and other composition is identical with embodiment 3 with method for making.
III, test example part
The mass analysis method of test example 1, compositions
Put down in writing multiple method of mupirocin being carried out Quality Evaluation Analysis in the prior art, European Pharmacopoeia 5.4 editions (EP5.4) and British Pharmacopoeias 2009 editions (EP2009) for example, these analytical methods all can be used for the Quality Evaluation Analysis that carries out the mupirocin raw material and comprise their preparations.
The mupirocin raw material related substance detection method of for example putting down in writing among the EP5.4 is as follows:
Related substance detects, and carries out according to high performance liquid chromatography.
Test solution: will contain the substance dissolves to be checked of the 50.0mg active component of having an appointment in mixed solvent (methanol mixes with 13.6g/l sodium acetate solution equal-volume, is adjusted to pH4.0 with acetic acid), and be diluted to 10ml with identical mixed solvent again.
Reference solution (a): the test solution of 1.0ml is diluted to 50.0ml with mixed solvent (methanol mixes with 13.6g/l sodium acetate solution equal-volume, is adjusted to pH4.0 with acetic acid).
Reference solution (b): with hydrochloric acid 10ml reference solution (a) is adjusted to pH2.0, places again 20h.
Reference solution (c): 25mg mupirocin lithium (CRS) is dissolved in mixed solvent (methanol mixes with 13.6g/l sodium acetate solution equal-volume, is adjusted to pH4.0 with acetic acid), is diluted to 200.0ml with identical mixed solvent again.
Use following equipment to carry out chromatographic run:
-chromatographic column: 0.25m is long, internal diameter 4.6mm, and implant is chromatographic grade octyl silane group silica gel (5 μ m),
-mobile phase: 20 volume water, 30 volume oxolanes and 50 volume 10.5g/l are mobile phase with the mixture that acetic acid is adjusted to the ammonium acetate solution of pH5.7 in advance, and flow velocity is 1ml/min,
-detector, ultraviolet spectrophotometer, wavelength 240nm.
In instrument, inject 20 μ l reference solutions (b).The 2nd peak and the peak-to-peak separating degree of mupirocin should be greater than 7 in two major impurity peaks in the reference solution (b).In instrument, inject 20 μ l reference solutions (c).Record chromatogram subject to the foregoing, the retention time of impurity C is about 0.75 for mupirocin.In instrument, inject 20 μ l test solutions and 20 μ l reference solutions (a).Continuous record test solution chromatogram is to 3.5 times of the mupirocin retention time.In the chromatogram of test solution: the peak area of impurity C is not more than 2 times (4%) of main peak area in reference solution (a) chromatogram; The area at other any peak except main peak and impurity C peak is not more than half (1%) of main peak area in reference solution (a) chromatogram; Whole peak area sums except main peak are not more than 3 times (6%) of main peak area in reference solution (a) chromatogram.Ignore 0.05 times of little peak than main peak area in reference solution (a) chromatogram.
Assay also can carry out with reference to said method.
The mupirocin raw material related substance detection method of for example putting down in writing among the BP2009 is as follows:
Determination of related substances:
(1) preparation of need testing solution and contrast solution: precision takes by weighing this product an amount of (being equivalent to approximately mupirocin 25mg), puts in the 50mL volumetric flask, and to add 0.1mol/L and pH be 6.3 phosphate buffer dissolving and be settled to scale, as need testing solution; Precision is measured need testing solution 1mL, puts in the 100mL volumetric flask, adds 0.1mol/L and pH and is 6.3 phosphate buffer and be diluted to scale, in contrast solution;
(2) chromatographic condition and system suitability: be filler (the rustless steel pre-column that adds C8) with octyl silane group silica gel; Take oxolane: 7.7g/L ammonium acetate (regulating pH value to 5.7 with glacial acetic acid) is (28:72) as mobile phase; The detection wavelength is 240nm, and mupirocin peak and its relative retention time are that the separating degree at 0.73 peak (mupirocin impurity C) must not be less than 3.5;
(3) measure: precision is measured need testing solution and each 20uL of contrast solution, and the injection liquid chromatography records chromatogram respectively.In the chromatogram of need testing solution, impurity C peak area must not be greater than 4 times (4%) of contrast solution main peak area; Impurity D (relative retention time 0.6) peak area must not be greater than 5 times (5%) of contrast solution main peak area; Impurity E (relative retention time 0.64) peak area must not be greater than 10 times (10%) of contrast solution main peak area; Other single impurity peak area must not be greater than 1.5 times (1.5%) of contrast solution main peak area; The total impurities peak area and must not be greater than 20 times (20%) of contrast solution main peak area; Ignore less than the peak of contrast solution main peak area 0.1 times (0.1%) in the need testing solution chromatogram.
The mensuration of mupirocin content:
(1) chromatographic condition and system suitability: be filler with octadecylsilane chemically bonded silica; Take acetonitrile: 0.05mol/L and pH as 6.3 phosphate buffers (28:72) as mobile phase; The detection wavelength is 230nm.Mupirocin peak and its relative retention time are that the separating degree at 0.75 peak (mupirocin impurity C) must not be less than 1.5;
(2) measure: precision takes by weighing this product an amount of (being equivalent to approximately mupirocin 12.5mg), puts in the 50mL volumetric flask, adds the mobile phase dissolving and is diluted to scale, shakes up, and filters, and precision is measured filtrate 20uL injection liquid chromatography, the record chromatogram; Other gets the mupirocin reference substance, measures with method.With calculated by peak area, namely get mupirocin content by external standard method.
For the present invention, the related substances and assay method is carried out with reference to the method among the BP2009 in the present composition, particularly when carrying out present composition related substance, carry out according to the chromatographic condition among the BP2009 and requirement, making chromatographic condition be adjusted to mupirocin peak and its relative retention time is that the separating degree at 0.73 peak (mupirocin impurity C) must not be less than 3.5; Then use the method among the BP2009, measure the test solution of the present composition, thereby can calculate the amount of some single impurity or the amount of total impurities.
The investigation of test example 2, boric acid consumption
The method of reference example 1, the ointment compositions basic recipe of every 100g is: mupirocin 2g, PEG4000 are that 18g, boric acid amount suitably change, PEG400 adds to 100g.Wherein in different formulations, the addition of boric acid is respectively (in the ointment compositions of every 100g): 0g, 0.01g, 0.025g, 0.05g, 0.075g, 0.1g, 0.2g, 0.3g, 0.5g, 0.6g, 0.8g, 1.0g, 1.25g, 1.5g, 1.75g, 2g, 2.5g, 3g, 5g.Obtain 19 ointment compositions.
These 19 ointment compositions sealings are loaded in the aluminum matter ointment tube, place 45 ° of C thermostats to place 50 days.Mensuration with respect to certain sample without for the high-temperature treatment, the variation multiple of the variation multiple of impurity C and total impurities in this sample.
Above-mentioned impurity C " variation multiple " refer to, for the sample of certain prescription, it is without 45 ° of C high-temperature treatments but place 4-8 ° of C refrigerator to place 50 days, and the impurity C percent of this moment is X1; This sample is X2 through 50 days rear impurity C of 45 ° of C high-temperature treatments percent, and then with the variation multiple of impurity C=X2 ÷ X1, this changes multiple more close to 1, represents that then the impurity variable quantity is less; When impurity C increased, this multiple was just greater than 1.Similarly, can calculate the variation multiple of total impurities.The prescription of different boric acid additions and impurity thereof change multiple and see the following form 1.The result shows that the amount of mineral acid only is to demonstrate good result in a certain amount of scope, and the excessive or too small equal nothing of addition is in the stability of product quality.
Table 1:
The investigation of test example 3, the present composition
Will be above each embodiment sample of " I, Preparation Example part " preparation and each reference examples sample of " II, reference examples part " preparation, its sealing is loaded in the aluminum matter ointment tube, place 80 ° of C thermostats to place 15 days.Reference test example 2 described methods are measured with respect to certain sample without for the high-temperature treatment variation multiple of the variation multiple of impurity C and total impurities in this sample.
The result shows, the variation times number average of various embodiments of the present invention sample impurity C is between 1.13 ~ 1.46, and for example the variation multiple of embodiment 1,2,4,7 impurity C is respectively 1.21,1.38,1.13 and 1.31; And the variation times number average of each reference examples sample impurity C is between 2.73 ~ 6.62, and for example the variation multiple of reference examples 1,4,6,7 impurity C is respectively 3.24,5.28,2.73 and 4.31.
In addition, the variation times number average of various embodiments of the present invention sample total impurities is between 1.25 ~ 1.50, and for example the variation multiple of embodiment 2,3,5,6 total impurities is respectively 1.33,1.50,1.43 and 1.31; And the variation times number average of each reference examples sample total impurities is between 3.03 ~ 8.55, and for example the variation multiple of reference examples 2,5,7 total impurities is respectively 3.75,6.77 and 4.54.
Above-described embodiment just illustrates of the present invention, and the present invention also can implement with other ad hoc fashion or other particular form, and does not depart from main idea of the present invention or substitutive characteristics.Therefore, the embodiment of description all should be considered as illustrative from any aspect but not be determinate.Scope of the present invention should be by additional claim explanation, and the intention of any and claim and the variation of scope equivalence also should be within the scope of the present invention.
Claims (10)
1. ointment medicament compositions wherein comprises: mupirocin shown in the following formula or the acceptable salt of its pharmacy, Polyethylene Glycol and mineral acid,
2. according to claim 1 ointment medicament compositions, it comprises mupirocin or the acceptable salt of its pharmacy, molecular weight is that 200 ~ 600 Polyethylene Glycol, molecular weight are 2000 ~ 6000 Polyethylene Glycol and mineral acid.
3. according to claim 1 to 2 ointment medicament compositions, the acceptable salt of the pharmacy of wherein said mupirocin is calcium salt or its solvate of mupirocin.
4. according to claim 1 to 3 ointment medicament compositions, the acceptable salt of the pharmacy of wherein said mupirocin is the dihydrate of the mupirocin calcium salt shown in the following formula:
5. according to claim 1 to 4 ointment medicament compositions, wherein said molecular weight is that 200 ~ 600 Polyethylene Glycol is that molecular weight is the Polyethylene Glycol of 200-400.
6. according to claim 1 to 5 ointment medicament compositions, wherein said molecular weight is that 2000 ~ 6000 Polyethylene Glycol is that molecular weight is the Polyethylene Glycol of 2000-4000.
7. according to claim 1 to 6 ointment medicament compositions, wherein said mineral acid is boric acid.
8. according to claim 1 to 7 ointment medicament compositions, wherein also comprise the acceptable adjuvant of optional pharmacy, for example warming regulator, antiseptic, thickening agent.
9. according to claim 1 to 8 ointment medicament compositions, comprise in its per 100 grams: mupirocin or the acceptable salt of its pharmacy: 0.5 ~ 5g,
Molecular weight is 2000 ~ 6000 Polyethylene Glycol: 10 ~ 30g,
Mineral acid: 0.01 ~ 2g,
The optional acceptable adjuvant of pharmacy: 0 ~ 5g, and
Molecular weight is 200 ~ 600 Polyethylene Glycol: an amount of, add to 100g;
Perhaps comprise:
Mupirocin or the acceptable salt of its pharmacy: 1 ~ 3g,
Molecular weight is 2000 ~ 6000 Polyethylene Glycol: 15 ~ 25g,
Mineral acid: 0.1 ~ 1g,
The optional acceptable adjuvant of pharmacy: 0 ~ 2g, and
Molecular weight is 200 ~ 600 Polyethylene Glycol: an amount of, add to 100g.
Perhaps comprise:
Mupirocin or the acceptable salt of its pharmacy: 1 ~ 3g,
Molecular weight is 2000 ~ 4000 Polyethylene Glycol: 15 ~ 25g,
Mineral acid: 0.1 ~ 1g,
The optional acceptable adjuvant of pharmacy: 0 ~ 2g, and
Molecular weight is 200 ~ 400 Polyethylene Glycol: an amount of, add to 100g.
Perhaps comprise:
Mupirocin: 1.5g
PEG4000： 18g
Boric acid: 0.25g
PEG400: an amount of, add to 100 grams;
Perhaps comprise:
Mupirocin: 2g
PEG3350： 19g
Boric acid: 0.5g
PEG400: an amount of, add to 100 grams;
Perhaps comprise:
Mupirocin: 2.5g
PEG3350： 20g
Boric acid: 0.75g
PEG300: an amount of, add to 100 grams;
Perhaps comprise:
Mupirocin: 3g
PEG3000： 15g
Boric acid: 1g
PEG600: an amount of, add to 100 grams;
Perhaps comprise:
Perhaps comprise:
Mupirocin: 2g
PEG6000： 15g
Boric acid: 0.5g
PEG200: an amount of, add to 100 grams;
Perhaps comprise:
Mupirocin: 2g
PEG4000： 15g
Boric acid: 0.6g
Borneolum Syntheticum: 0.5g
PEG300: an amount of, add to 100 grams;
Perhaps comprise:
Perhaps comprise:
Mupirocin calcium: 3g
PEG2000： 25g
Boric acid: 0.6g
PEG400: an amount of, add to 100 grams;
Perhaps comprise:
Mupirocin: 2.5g
PEG4000： 15g
Boric acid: 0.2g
Herba Menthae: 0.2g
PEG200: an amount of, add to 100 grams.
10. prepare the method for the described ointment medicament compositions of claim 1-9, it may further comprise the steps:
(1) making mineral acid and the optional acceptable adjuvant of pharmacy be dissolved in an amount of molecular weight is in 200 ~ 600 the Polyethylene Glycol, to obtain mixture;
(2) in the mixture of step (1), add mupirocin or the acceptable salt of its pharmacy, stirring and dissolving;
(3) be that 2000 ~ 6000 Polyethylene Glycol is heated to melting with molecular weight, then it under agitation joined in step (2) the gained material, stir;
(4) add molecular weight be 200 ~ 600 Polyethylene Glycol to full dose, mix homogeneously, and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104205995A CN102871955B (en) | 2012-10-29 | 2012-10-29 | Ointment medicament composition containing mupirocin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104205995A CN102871955B (en) | 2012-10-29 | 2012-10-29 | Ointment medicament composition containing mupirocin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102871955A true CN102871955A (en) | 2013-01-16 |
| CN102871955B CN102871955B (en) | 2013-11-13 |
Family
ID=47473633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104205995A Active CN102871955B (en) | 2012-10-29 | 2012-10-29 | Ointment medicament composition containing mupirocin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102871955B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412000A (en) * | 2015-11-23 | 2016-03-23 | 安徽新和成皖南药业有限公司 | Preparation method for mupirocin ointment |
| CN110772479A (en) * | 2019-11-20 | 2020-02-11 | 湖北人福成田药业有限公司 | Mupirocin ointment and preparation method thereof |
| CN111220721A (en) * | 2019-12-06 | 2020-06-02 | 湖北人福成田药业有限公司 | Mupirocin ointment impurity qualitative positioning and testing method and application |
| WO2021120268A1 (en) * | 2019-12-17 | 2021-06-24 | 福元药业有限公司 | Mupirocine ointment and preparation method therefor |
| CN114053210A (en) * | 2021-10-26 | 2022-02-18 | 海南全星制药有限公司 | Mupirocin ointment and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335122A (en) * | 2011-06-21 | 2012-02-01 | 北京协和药厂 | Mupirocin ointment and preparation method thereof |
-
2012
- 2012-10-29 CN CN2012104205995A patent/CN102871955B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335122A (en) * | 2011-06-21 | 2012-02-01 | 北京协和药厂 | Mupirocin ointment and preparation method thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412000A (en) * | 2015-11-23 | 2016-03-23 | 安徽新和成皖南药业有限公司 | Preparation method for mupirocin ointment |
| CN110772479A (en) * | 2019-11-20 | 2020-02-11 | 湖北人福成田药业有限公司 | Mupirocin ointment and preparation method thereof |
| CN111220721A (en) * | 2019-12-06 | 2020-06-02 | 湖北人福成田药业有限公司 | Mupirocin ointment impurity qualitative positioning and testing method and application |
| WO2021120268A1 (en) * | 2019-12-17 | 2021-06-24 | 福元药业有限公司 | Mupirocine ointment and preparation method therefor |
| CN114053210A (en) * | 2021-10-26 | 2022-02-18 | 海南全星制药有限公司 | Mupirocin ointment and preparation method thereof |
| CN114053210B (en) * | 2021-10-26 | 2023-09-29 | 海南全星制药有限公司 | Mopirocin ointment and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102871955B (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102871955B (en) | Ointment medicament composition containing mupirocin | |
| CN101478964B (en) | Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
| CN101808516B (en) | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | |
| JP6080312B2 (en) | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | |
| CN102885763B (en) | Mupirocin ointment pharmaceutical composition | |
| TR201802093T4 (en) | Combination of act inhibitor compound and abiraterone for use in therapeutic therapies. | |
| CN102335122B (en) | Mupirocin ointment and preparation method thereof | |
| US20230285334A1 (en) | Therapeutic compounds, formulations, and uses thereof | |
| WO2016092561A2 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
| CN101485625B (en) | Amoluofen emulsifiable paste | |
| CN105663062B (en) | A kind of flupentixol and melitracen pharmaceutical composition and preparation method thereof | |
| CN102784382B (en) | Argatroban drug composition and preparation method and application of argatroban drug composition | |
| CN103553996A (en) | Anticholinergic pharmaceutical composition | |
| CN101584661A (en) | Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof | |
| CN104292242B (en) | Pyrantel compound and preparation, as well as preparation method and application of pyrantel compound and preparation | |
| CN103845332A (en) | Medicinal dasatinib composition and preparation method thereof | |
| CN103655460B (en) | Injection medicinal composition containing aztreonam, as well as preparation method and application thereof | |
| CN103724359B (en) | A kind of amorphous cefotetan acid and prepared the method for Cefotetan Disodium and containing the pharmaceutical composition of this Cefotetan Disodium by it | |
| CN104940189B (en) | The composition for treating hyperplasia disease | |
| CN102727426A (en) | Emulsifiable paste for treating non-infectious inflammatory dermatosis and method for preparing emulsifiable paste | |
| CN105777711B (en) | A kind of pharmaceutical co-crystals body and preparation method thereof of Lomefloxacin and 5-F- M-phthalic acids | |
| CN110452224A (en) | Pyrimidine azoles alcohol compound and its preparation method and application | |
| CN113307777B (en) | Alogliptin benzoate intermediate and preparation method of Alogliptin benzoate | |
| CN110023318A (en) | The crystal form of compound | |
| CN106310286A (en) | Tosufloxacin tosylate composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |